Majors: MKT/HRM/FIN/SCM (FINANCE)
S.No. (F5)

"*Impact of Financial Leverage on Financial Performance of Pharmaceutical Industry in Pakistan*"

By:

(MEHMOOD HUSSAIN) ***(01-321222-018)***

Supervisor:

(Dr. Lubna Maroof)

Department of Business Studies
Bahria University Islamabad

Fall 2023

FINAL PROJECT/THESIS APPROVAL SHEET

Viva-Voce Examination

Viva Date 29/01/2024

Topic of Research: (***Impact of Financial Leverage on Financial Performance of Pharmaceutical Industry in Pakistan***)

Names of Student (Mehmood Hussain): Enroll # 01-321222-018

-
-
-

Class: (MBA 1.5)

Approved by:

_____

(DR.LUBNA MAROOF)

Supervisor

_____

(Dr.Khalil Ullah Mohammad)

Internal Examiner

_____

(OMER SAJID)

External Examiner

_____

Dr.Syed Haider Ali Shah

Research Coordinator

_____

Dr.Khalil Ullah Mohammad

Head of Department

Business Studies

ACKNOWLEDGMENT

I am very thankful and would like to prompt my heartfelt thankfulness to my Supervisor Dr.Lubna Maroof for her solid support, helpful guidance, and perceptive feedback throughout the entire research process. Special thanks to my family and friends for their encouragement and kind support during the challenging moments. Additionally, I extend my appreciation to Pakistan Pharmaceutical sector for their contributions to this thesis. This journey would not have been possible without all of these amazing people's support. I want to thank everyone for being a crucial part of my academic journey.

Table of Contents

ABSTRACT

This thesis investigates the correlation between financial leverage and the financial performance of the pharmaceutical industry in Pakistan. The pharmaceutical industry plays a vital role in global healthcare, offering essential goods and services for a wide range of medical conditions. The term financial leverage describes the degree to which an Investor or a industry is using the borrowed money in their business. The study focuses on ten pharmaceutical companies listed at Pakistan Stock Exchange (PSX).We analyzed the impact by utilizing their annual financial reports spanning data from 2012 to 2022. The primary objective is to assess the impact of financial leverage, as an independent variable measured by debt to equity ratio, on the financial performance, measured by Return on Assets (ROA), as the dependent variable. The control variables are firm size, liquidity and GDP. The research adopts a multiple statistical tool, combining descriptive statistics, correlation analysis, and regression analysis to analyze and interpret the collected data. The findings reveal a noteworthy negative relationship between financial leverage and financial performance across the selected pharmaceutical companies. This implies that as financial leverage increases, the financial performance, as assessed by ROA, tends to decrease. The thesis presents some policy implications and suggestions for regulators, law-makers, and multinational companies (MNCs) to lessen the negative effect of financial leverage on their financial performance.

CHAPTER: 01

1. INTRODUCTION

1.1. BACKGROUND OF THE STUDY

There was no pharmaceutical sector in Pakistan when the nation attained independence in 1947. Now, there are more than 800 pharmaceutical production facilities in Pakistan. Include those run by 25 international corporations. The pharmaceutical industry plays a vital role in global healthcare, offering essential goods and services for a wide range of medical disorders. In Pakistan, this sector has witnessed considerable expansion, emerging as a substantial contributor to the country's economic well-being. With its ongoing growth, the industry faces a mix of challenges and opportunities, one of which is the strategic utilization of financial leverage, a factor that can significantly influence its financial performance. The pharmaceutical industry in Pakistan is valued at $3.10 billion (equivalent to Rs. 325,596 billion according to IMS data). In comparison to the estimated total global pharmaceutical market size, which exceeds $1 trillion, Pakistan's pharmaceutical market constitutes a relatively small portion, accounting for only around 0.5 percent. In the Pakistani market, pharmaceutical product sales have exhibited robust expansion over the years. For instance, between 2012 and 2017, it is estimated that the Compound Annual Growth Rate (CAGR) was approximately in the range of 10 to 12 percent About 90,000 people are directly employed in this business, while 150,000 more are employed indirectly in a variety of roles... Pharmaceutical manufacturers in Pakistan benefit from a well-established resource base that facilitates business operations. Despite the fact that a significant portion of the raw materials, approximately 95 percent, needs to be imported, the accessibility to these resources remains relatively easy. To support the industry, the government has implemented measures to simplify the importation of raw materials by gradually reducing duties over time. The industry has expressed its appreciation for the proposed budget, which suggests further reductions in duties, signaling a positive development for the sector.

The pharmaceutical industry in Pakistan holds a pivotal role in both the nation's healthcare system and economic landscape. Examining the financial intricacies, (Rizwan, Hassan, Asrar,

Mahar 2019)explores the effect of financial leverage on the industry's performance, employing key ratios

Like debt to equity, return on assets, and net profit margin. Unveiling significant associations, the study reveals the nuanced relationships among capital structure and performance indicators within pharmaceutical firms in Pakistan. In parallel**,** (Jannat, Shafiq, Riasat, 2023) provides a broader perspective on the industry's strengths, weaknesses, and growth potential. The sector, while establishing itself in the Asian market, grapples with challenges related to quality control and innovation. Recognizing a gap in existing knowledge, this thesis adopts a mixed-methods approach, synthesizing financial insights with a broader understanding of the industry's landscape to offer a holistic perspective. By bridging this gap, the research aims to provide a comprehensive toolkit for stakeholders, policy makers, and industry players navigating the complexities of the pharmaceutical sector in Pakistan, contributing to its sustained growth and resilience.

There is a need and relevance for this study in Pakistan, as there are no studies on the subject of financial leverage's effect on the financial performance of the pharmaceutical business. This presents an opportunity for us to investigate the relationship surrounding the aforementioned issue. In Pakistan, companies utilize financial leverage as a means to fulfill their financing requirements. However, they often lack an understanding of its impact on their financial performance and, consequently, its potential to enhance shareholder returns. This raises the question of determining the optimal level of leverage. This optimal level hinges on their ability to generate sales sufficient to cover their debt obligations and is also contingent on the prevailing economic conditions in Pakistan. Conducting research in this area would offer valuable insights to companies, enabling them to assess their financial needs, borrowing capacity, and how this contributes to delivering returns to shareholders. Ultimately, such insights can contribute to the economic growth of Pakistan. The amount that a company uses debt and equity to fund its assets is measured by financial leverage. A firm may use both debt and equity to finance its investments. Preference capital may also be used by the business. These sources of financing enable a company to allocate capital to its various assets. Notably, the interest rate on debt remains constant regardless of the company's overall return on assets. The strategic use of financial leverage by a company aims to generate returns on the borrowed

funds that exceed their associated costs. Consequently, as a company takes on more debt, its level of financial leverage escalates. Various research studies have revealed that the degree of financial leverage exerts a discernible impact on the overall performance of publicly-traded pharmaceutical firms in Pakistan.

Financial leverage, which involves using debt to finance company operations and investments, can have both positive and negative consequences. While it can amplify returns and facilitate growth, it also exposes companies to higher financial risks. The pharmaceutical sector need a balance between debt and equity financing due to its high expenditures associated with research and development, regulatory constraints, and ongoing innovation demands. The interaction between financial leverage and performance in the pharmaceutical sector, especially in Pakistan, is of significant interest to industry players and researchers.

The utilization of financial leverage in the Pakistani pharmaceutical industry is noteworthy due to various factors. The industry is characterized by intense competition, as numerous multinational and local companies strive to gain a competitive advantage. The growth and market presence of these companies are heavily influenced by financial decisions. Moreover, the presence of strict regulatory guidelines requires a careful equilibrium between innovation, compliance, and profitability. Given this intricate landscape, the pharmaceutical industry provides an ideal scenario for examining the effects of financial leverage on financial performance. The objective of this study is to examine the correlation between financial leverage and the financial performance of pharmaceutical companies operating in Pakistan. The primary inquiries revolve around the utilization of financial leverage by these companies, the factors that impact their financing choices, and the implications of these decisions on their financial performance. This research will delve into the distinctive dynamics of the pharmaceutical sector in Pakistan, as well as the economic, regulatory, and market influences that shape financial decisions within this particular context. Increasing financial leverage leads to an increase in finance costs. Consequently, high finance costs have a negative impact on earnings per share. The decrease in EPS is attributed to the higher interest payments resulting from the increased financial leverage. Previous studies have demonstrated both a positive and negative correlation between financial performance and financial leverage. This research aims to investigate the correlation between financial performance and financial leverage.

The pharmaceutical industry in Pakistan stands at a critical juncture, marked by a delicate balance between financial dynamics and the broader landscape of economic and healthcare imperatives. This introduction seeks to provide a comprehensive overview of the pharmaceutical sector in Pakistan, integrating insights from recent research articles that shed light on both its financial performance and overall industry dynamics.

The amount that a company uses debt and equity to fund its assets is measured by financial leverage. A industry may use both debt and equity to finance its investments. Preference capital may also be used by the business. These sources of financing enable a company to allocate capital to its various assets. Notably, the interest rate on debt remains constant regardless of the company's overall return on assets. The strategic use of financial leverage by a company aims to generate returns on the borrowed funds that exceed their associated costs. Consequently, as a company takes on more debt, its level of financial leverage escalates. Various research studies have revealed that the degree of financial leverage exerts a discernible impact on the overall performance of publicly-traded pharmaceutical firms in Pakistan.

In light of these insights, this thesis seeks to unravel the multifaceted dimensions of the pharmaceutical industry in Pakistan. By integrating financial leverage dynamics with a broader understanding of the industry's strengths, weaknesses, and growth potential, the research aims to contribute a holistic perspective. As the industry navigates challenges and opportunities, a nuanced examination becomes imperative to inform strategic decision-making, policy formulation, and sustainable growth (Jannat, Shafiq, Riasat, 2023). Through a quantitative-method approach This study endeavors to capture the essence of the pharmaceutical landscape in Pakistan, shedding light on the intricacies that define its financial performance and industry dynamics.

1.2. RATIONALE:

This thesis on the pharmaceutical industry in Pakistan is motivated by the need to comprehensively understand the complex dynamics influencing the sector's performance and growth. The rationale for this research is twofold. Firstly, recent studies (Jannat, Shafiq, Riasat, 2023) (Rizwan, Hassan, Asrar, Mahar 2019) have individually explored financial leverage dynamics and industry strengths and weaknesses, but there is a noticeable gap in the literature that integrates these perspectives. By combining insights from financial leverage studies with a

broader analysis of the industry landscape, this research aims to provide a more holistic understanding, offering nuanced insights into the interplay between financial structures and overall industry dynamics. Secondly, as the pharmaceutical sector in Pakistan faces evolving challenges and opportunities, informed decision-making is crucial for its sustainable development. This study seeks to bridge existing knowledge gaps, contributing to the strategic decision-making processes of stakeholders, policymakers, and industry participants, ultimately fostering a resilient and thriving pharmaceutical industry in Pakistan.

1.3. PROBLEM STATEMENT:

The pharmaceutical industry in Pakistan stands at a crucial stage, directing multidimensional challenges and opportunities. While existing researches have provided valuable insights into the financial dynamics and overall industry landscape, but still there remains a significant gap in understanding the effect of financial leverage, on the financial performance of pharmaceutical firms. To adjacent the present research gap, in-depth study is required on the correlation among financial leverage and financial performance of pharmaceutical industry in Pakistan. With a focus on the following research question: What effect the financial leverage have on the financial performance of Pakistani Pharmaceutical industry? This study pursues to explore the relationship between financial leverage and the financial performance of Pharmaceutical companies in Pakistan.

.

1.4. RESEARCH QUESTIONS:

What is the impact of financial leverage on financial performance of pharmaceutical industry in Pakistan?

1.5. RESEARCH OBJECTIVES:

To explore the impact of financial leverage on financial performance and measure its effect on listed Pharmaceutical companies in Pakistan, this study aims to contribute to the understanding of the relationship between financial leverage and financial performance. A robust and effective decision-making process for a firm's financial policies is crucial for progressive economic development in a country. Capital structure, as a key component of strategic financial decision-making, holds significant importance. The study will delve into the various economic and

institutional factors influencing the direction of the economy, and how these factors play a pivotal role in shaping firms' decisions regarding leverage. The primary objective is to investigate and analyze the correlation between financial leverage and financial performance in the context of the listed Pharmaceutical companies in Pakistan.

1.6. RESEARCH HYPOTHESIS:

Hypothesis H-1

There is a negative relationship between financial leverage and financial performance of the Pharmaceutical companies operating in Pakistan.

1.7. NEED AND SIGNIFICANCE OF THE STUDY

We have the chance to investigate the relationship between financial leverage and financial performance in the context of pharmaceutical companies listed on the Karachi Stock Exchange, as there aren't many studies on the subject in Pakistan. Companies employ financial leverage as a means to fulfill their financing requirements. However, there appears to be a lack of awareness regarding the impact of this leverage on their financial performance and its potential to enhance shareholders' returns. An essential question arises: to what extent should leverage be utilized? The answer to this question is contingent on their capability to generate sales that can cover the debt obligations. Moreover, it is also influenced by the prevailing economic conditions in Pakistan. This research has the potential to offer valuable insights to companies, helping them analyze their financial needs, determine their borrowing capacity, and understand how such practices can contribute to boosting returns for shareholders, ultimately benefiting the overall economic growth of Pakistan.

CHAPTER: 02

LITERATURE REVIEW

2.1 Introduction

This section covers the literature on the impact of financial leverage on financial performance of pharmaceutical industry in Pakistan.

2.1.1 Introduction to Financial Leverage:

A key idea in corporate finance is financial leverage, which is the use of borrowed or debt money to increase the possible returns on stock. It involves employing external funds to augment a company's capital base, thus magnifying the impact of financial decisions on the shareholders' equity. The significance of financial leverage lies in its ability to enhance returns and increase the shareholders' earnings, but it also introduces a level of financial risk that requires careful consideration.

2.1.2 Significance in Financial Management:

In the realm of financial management, the strategic use of financial leverage plays a pivotal role in shaping a company's capital structure. Capital structure refers to the mix of equity and debt that a company employs to finance its operations and investments. The decision to utilize financial leverage is influenced by the pursuit of an optimal capital structure, balancing the benefits of increased returns against the potential drawbacks of higher financial risk.

Financial leverage provides companies, including those in the pharmaceutical industry in Pakistan, with the opportunity to access additional capital beyond their equity base. This additional capital can be utilized for various purposes, such as funding research and development initiatives, expanding production capacities, or exploring new markets. By leveraging external funds, pharmaceutical firms can potentially achieve higher returns on investment than if they were to rely solely on equity financing.

2.1.3 Enhancing Returns and Associated Risks:

The primary goal of employing financial leverage is to magnify returns on equity. When a company generates profits using borrowed funds, the returns to shareholders exceed what they would have earned without the use of leverage. This is commonly referred to as the "leverage effect." By leveraging their capital, pharmaceutical companies can optimize their financial structure to achieve a balance between equity and debt, aiming for an efficient level that maximizes returns for shareholders.

However, the use of financial leverage comes with inherent risks. One of the key risks is the obligation to pay interest and principal on borrowed funds, irrespective of the company's profitability. High levels of debt can lead to increased financial fragility, particularly during economic downturns or unforeseen industry challenges. Therefore, the prudent management of financial leverage requires a careful assessment of risk tolerance, market conditions, and the overall financial health of the company.

The pharmaceutical industry in Pakistan holds a pivotal role in both the nation's healthcare system and economic landscape. Numerous studies have delved into the implications of financial leverage on corporate performance. Examining the financial intricacies, (Rizwan, Hassan, Asrar, Mahar 2019) explores the impact of financial leverage on the industry's performance, employing key ratios such as debt to equity, return on assets, and net profit margin. Unveiling significant associations, the study reveals the nuanced relationships between capital structure and performance indicators within pharmaceutical firms in Pakistan.

(S. S. Rehman 2013) conducted research on the influence of financial leverage on the financial performance of Pakistan's sugar sector. They showed that financial leverage had a mixed effect on the financial performance of Pakistan's sugar business in their article, "Relationship between Financial Leverage and Financial Performance: Empirical Evidence of Listed Sugar Companies of Pakistan." The findings indicate a negative correlation between the debt-to-equity ratio and earnings per share, net profit margin, and return on equity, and a positive correlation between the debt-to-equity ratio with sales growth and return on asset. Throughout the research period (2006-2011), the debt-to-equity ratio showed notable variability, indicating large swings in the

data. Return on equity and net profit margin also shown significant variations. On the other hand, return on assets and profits per share (EPS) showed.

The "Impact of Financial Leverage on the Performance of Pharmaceutical Firms in Pakistan," delves into the intricate link between financial leverage and the performance of pharmaceutical firms in the country. Utilizing significant financial ratios such as debt to equity ratio, return on assets (ROA), the study uncovers nuanced connections. Notably, it reveals a noteworthy impact of financial leverage on pharmaceutical firms, where the debt ratio exhibits a negative relationship with net profit margin (NPM), while the equity ratio demonstrates a positive association with return on assets (ROA) (Rizwan, Hassan, Asrar, Mahar 2019). These findings imply a complex interplay between financial structures and performance indicators within the pharmaceutical industry in Pakistan. Complementing this financial lens, then, one of the studies, "Pakistan's Pharmaceutical Industry: Strengths, Weaknesses, and Growth Potential," (Jannat, Shafiq, Riasat, 2023) offers a broader perspective on the pharmaceutical landscape. This article provides a comprehensive analysis of the industry's strengths and weaknesses, emphasizing its nascent yet burgeoning presence in the Asian market. As it details the types of drugs produced in Pakistan, the article underscores the industry's pivotal role in the country's medical system. (Rizwan, Hassan, Asrar, Mahar 2019) Moreover, it highlights the industry's potential for innovation and growth while advocating for governmental measures to enhance the quality of pharmaceutical products.

2.2 Financial Performance

A firm's ability to produce revenue from its primary business mode is measured by its financial performance. Investors and analysts may want to dig further into financial records to find margin growth rates (Hales, 2005) financial performance metrics that are often used in practice include net asset value, operational income, and earnings before interest and taxes. It is crucial to remember that no one financial performance metric should be used in isolation. Instead, a comprehensive evaluation of a business's success should consider a wide range of metrics.

Traditional management studies categorize ratios based on profitability, liquidity, leverage, and efficiency performance characteristics that are measured (Richard et al., 2009). Financial statement data may be used to directly compute these ratios. The conventional classification of ratios is supplemented with valuation ratios, which include more recent evaluations of the

company's "value" by the market. Ratios are computed using basic income statement and balance sheet components to examine financial statements of financial entities.

2.2.1 Introduction to ROA as a Financial Performance Metric:

Return on Assets (ROA) is a key financial metric that assesses a company's capacity to make profits from its assets. It is calculated by dividing net income by average total assets, providing insights into the efficiency with which a company utilizes its assets to generate earnings. In the context of the pharmaceutical industry in Pakistan, ROA serves as a critical indicator of operational efficiency and financial performance.

2.2.2 Significance in Financial Management:

ROA holds significant importance in financial management as it directly reflects a company's operational efficiency and asset utilization. The metric is key component of overall financial analysis, helping stakeholders understand how effectively a pharmaceutical company is deploying its assets to generate profits. An increasing ROA is generally indicative of improved operational efficiency, while a declining ROA may signal potential operational challenges or inefficiencies.

The study conducted by (Iqbal, U., & Usman, M. 2018) investigated the relationship between financial leverage and the performance of Pakistani textile composite companies. The study used a 5-year dataset, with a representative sample of the top 16 corporations, covering the years 2011 to 2015. The investigation's goal was to provide insights by using regression modeling, correlation analysis, and descriptive statistics. The results showed a significant inverse relationship between financial leverage and return on equity (ROE) for a company. Furthermore, financial leverage and Return on Assets (ROA) showed a strong and favorable correlation. The study made clear that higher interest rates and a larger debt load had a negative influence on stock value, which in turn had a negative effect on the performance of the entire company...

Researchers (Enekwe, C. I., Agu, C. I., & Eziedo, K. N 2014) are this study examined the effects of financial leverage on the financial performance of a subset of Nigerian pharmaceutical companies between 2001 and 2012, with a particular focus on three important financial leverage indicators: interest coverage ratio (ICR), debt-equity ratio (DER), and debt ratio (DR). Return on

Assets (ROA) was the dependent variable taken into consideration. Secondary data were obtained from the Comprehensive Income Statement and Statement of Financial Position of the pharmaceutical businesses listed on the Nigerian Stock Exchange (NOSE) using an ex post facto research approach. The study found that while interest coverage ratio (ICR) showed a positive association with Return on Assets (ROA), debt ratio (DR) and debt-equity ratio (DER) showed a negative correlation. Descriptive statistics, Pearson correlation, and regression analyses were used in the analysis. Still,

M. A. Hoque (2017). The objective of this research is to investigate the relationship between financial performance and financial leverage within a specific set of Bangladeshi textile firms. With return on assets and return on capital serving as indicators of financial performance, and debt-assets and debt-equity ratios as stand-ins for financial leverage, the study uses SPSS-20 to perform correlation and regression analyses on a five-year dataset covering the years 2008 to 2012. The debt-to-equity ratio and return on assets show a statistically significant negative association (-.293), but the relationship with return on capital employed shows an insignificantly negative correlation (-.249). Moreover, a statistically significant negative correlation is shown between the debt-assets ratio and return on capital employed (-.335) as well as return on assets (-.285). Interestingly, the research ends

(Paul 2017). The present study's results highlight the interdependence of financial performance metrics, highlighting significant correlations between Return on Equity (ROE), Return on Assets (ROAD), Net Profit Margin, and Assets Turnover. The investigators observed a noteworthy impact of ROE on ROA, Net Profit Margin, and Assets Turnover, underscoring its crucial function in moulding the comprehensive financial outcome. Furthermore, ROA was shown to be an important variable, showing relevance when compared to ROE, Net Profit Margin, and Asset Turnover. The study also demonstrated the significant influence that Net Profit Margin has on ROE, ROA, and Asset Turnover, highlighting the importance of this metric in evaluating financial performance. Likewise, Assets Turnover proved important in terms of ROE, ROA, and Net Profit Margin, clarifying its crucial function in assessing financial leverage and overall

Bhadra, H. K., Karim, R., and Chakrobortty, T. The FGLS regression model was utilized in this study's panel quantitative analysis to evaluate the financial performance of pharmaceutical businesses listed on the Dhaka Stock Exchange (DOSE) and explore their interactions with one

another. The study period covered from 2001 to 2020. We discover that financial performance metrics like Return on Capital Employed (ROCE) and Return on Equity (ROE) have an inverse connection with measures of leverage, such as short-term debt (STD) and long-term debt (LTD). There is a statistically significant relationship between LTD and financial performance. Furthermore, there is a negative link between business size (SIZE) and financial performance, although there is a positive correlation between firm growth (GROWTH) and industry longevity (AGE) with ROCE and ROE. These empirical findings imply that pharmaceutical companies in Bangladesh have better.

The relationship between capital structure and the financial performance of pharmaceutical businesses listed on the Pakistan Stock Exchange was examined by (Rehan, M., Karaca, S. S., & Alvi, J 2020). Additionally, the study aims to investigate in detail how debt-to-equity ratios relate to important financial metrics including return on equity, earnings per share, gross profit, and return on capital. The results of this study indicate that there is a negative correlation between capital structure and profitability, implying that a rise in debt capital is associated with a decrease in organizational profitability and vice versa. Furthermore, the findings show that capital—debt or equity—does not significantly and positively correlate with return on equity. The analysis comes to the conclusion that changes in debt or equity financing have little to no impact on

(Abubakar 2020), A. According to research, there is no discernible relationship between the long-term debt ratio (LTDR) and the short-term debt ratio (STDR) and financial success as measured by ROE. TDER, on the other hand, stands out as a remarkable variable since it has a statistically significant negative impact on financial success. This suggests that a decline in shareholders' wealth, as measured by ROE, is linked to a greater level of financial leverage in the capital structure of listed oil and gas companies in Nigeria. This study explores the effects of financial leverage on the financial performance of seven Nigerian oil and gas companies that are publicly traded between 2005 and 2016. Utilizing secondary data taken from yearly reports and the daily official listings of the Nigerian Stock Exchange (NOSE),

In navigating the complexities of the pharmaceutical landscape in Pakistan, this literature review serves as a compass, guiding our exploration into the critical factors that shape the financial performance of pharmaceutical firms. The interconnected realms of financial leverage

and product personalization stand as focal points, influencing strategic decisions and industry dynamics. Drawing from a diverse array of studies, we embark on a journey that unravels the nuanced relationships between financial structures, market strategies, and overall industry health. From the profound impact of leverage on profitability to the nonlinear effects of product personalization on shareholder wealth, each study adds a layer to our understanding. Additionally, insights from industry overviews, growth strategies, and market projections contextualize these findings within the dynamic landscape of the Pakistani pharmaceutical sector. As we synthesize these diverse perspectives, this literature review lays the foundation for a comprehensive examination, providing valuable insights for stakeholders, policymakers, and industry participants.

2.3 Financial Leverage and Profitability:

Financial leverage and profitability are important concepts in finance that are closely related to a company's capital structure and its ability to generate returns for its shareholders. Let's explore each concept:

Financial Leverage:

Financial leverage refers to the use of debt or borrowed capital to increase the size of an investment or an operation. By using debt, a company can amplify its potential returns, as it can invest more than its equity alone would allow. Types of financial leverage include debt leverage (using borrowed funds) and operating leverage (using fixed costs like rent, salaries, etc.).

Key Points:

Pros of Financial Leverage:

Increases potential returns on equity for shareholders.

Allows companies to take advantage of investment opportunities that might increase shareholder wealth otherwise be unattainable.

Cons of Financial Leverage:

Increases financial risk: If the returns on the investment are lower than the cost of debt, it can lead to financial distress. Interest payments on debt are fixed, which can be a burden during economic downturns or periods of low profitability.

Profitability: Profitability measures a company's ability to generate earnings relative to its expenses and other costs over a specific period.

Key profitability ratios include:

Net Profit Margin: Net profit divided by revenue, indicating the percentage of revenue that remains as profit after all expenses. Return on Equity (ROE): Net income divided by shareholders' equity, measuring the return generated on shareholders' investments. Return on Assets (ROA): Net income divided by average total assets, assessing the efficiency of asset utilization.

Relationship between Financial Leverage and Profitability:

While financial leverage can amplify returns, it also introduces fixed costs in the form of interest payments. A company needs to generate profits above the cost of debt to ensure positive returns for shareholders. The impact of financial leverage on profitability depends on the success of the investments financed by debt. In summary, financial leverage can enhance returns but comes with increased risk, especially if profitability is not sufficient to cover the costs of debt. Companies need to strike a balance between using leverage to optimize returns and managing the associated risks to ensure long-term sustainability.

Our journey into the labyrinth of the pharmaceutical industry in Pakistan begins with a meticulous examination conducted by MISU, focusing on the pivotal interplay between financial leverage and the profitability of pharmaceutical companies. Spanning the temporal scope from 2008 to 2012, this study serves as a critical lens through which we scrutinize the financial landscape of these firms. The revealed outcome, a discernible negative effect of leverage on profitability, becomes a significant waypoint in our exploration. This finding resonates harmoniously with our overarching objective: to unravel the intricate mechanisms through which financial leverage influences the broader financial performance of pharmaceutical firms operating within the distinctive contours of Pakistan's pharmaceutical terrain.

As we delve into the nuanced dynamics brought to light by the research, questions emerge, beckoning us to comprehend the root causes and contextual intricacies that define this negative relationship. The study becomes more than a mere observation; it transforms into a key puzzle piece in our quest to decipher the financial complexities that underpin the pharmaceutical industry in Pakistan. The negative impact observed prompts us to seek a deeper understanding of how financial leverage, a seemingly integral aspect of financial management, interacts with and potentially shapes the economic fortunes of these pharmaceutical entities (MISU 2013). Thus, this study not only aligns seamlessly with our research objective but also marks the commencement of a more profound exploration into the multifaceted nature of financial performance within this sector.

Our expedition into the intricate realm of the pharmaceutical industry in Pakistan takes a divergent path with a comprehensive analysis conducted by (Ben-Jebara, Mishra, B. Modi, Mahar 2023). This study serves as a beacon, guiding our exploration into the effects of product personalization focus on shareholder wealth within the pharmaceutical sector. Spanning an unspecified timeframe, the research introduces a nuanced perspective—an exploration of the nonlinear impact of product personalization. The study unfolds a narrative suggesting that benefits accrue up to a certain threshold, beyond which drawbacks become apparent.

This revelation marks a crucial juncture in our quest, aligning harmoniously with the overarching research objective of dissecting the relationship between product personalization and shareholder wealth in the unique context of the Pakistani pharmaceutical landscape. As we delve into the specifics of this nonlinear impact, the study propels us into a contemplative phase, urging us to discern the point at which the benefits plateau and the drawbacks manifest. This nuanced understanding becomes a critical asset, offering insights that go beyond a mere binary perspective of product personalization's impact on shareholder wealth (Ben-Jebara, Mishra, B. Modi, Mahar 2023). The research contributes a dynamic layer to our exploration, pushing us to investigate not only the presence or absence of a relationship but the delicate balance that characterizes it. The study becomes more than a report on outcomes; it becomes a guide for our endeavor to comprehend the intricacies that govern strategic decisions within the pharmaceutical sector. In this intricate dance between product personalization and shareholder wealth, this study lays the groundwork for a detailed examination, providing a compass as we

navigate the complexities of strategic decision-making within the Pakistani pharmaceutical industry.

(Ahmad, N., Salman, A., & Shamsi, A 2015) research investigate the Impact of Financial Leverage on Firms' Profitability: An Investigation from Cement Sector of Pakistan

, this study delves into the potential stochastic connection between financial leverage and profitability. Employing an ordinary least squares (OLS) model, the analysis draws upon a rich dataset encompassing six years (2005-2010) and involves an impressive 108 observations derived from 18 out of 21 leading cement manufacturers in Pakistan. The findings reveal a statistically significant inverse relationship between financial leverage and profitability at a remarkable 99% confidence interval. These results contribute to the ongoing dialogue surrounding the potential trade-offs inherent in leveraging debt within the context of the Pakistani cement industry

2.4 Overview of the Pharmaceutical Industry in Pakistan:

Our comprehensive exploration into the multifaceted world of the pharmaceutical industry in Pakistan gains additional depth with a foundational overview sourced from Wikipedia. Serving as a comprehensive compendium, this resource encapsulates historical facets, challenges, and the regulatory framework that shapes the landscape of the pharmaceutical sector in Pakistan. This comprehensive summary becomes a pivotal guidepost, offering a rich contextual understanding. By unraveling the historical tapestry, we gain insights into the evolution of the pharmaceutical industry, contextualizing its growth, challenges, and transformative moments. This historical perspective becomes instrumental in shaping our understanding of the industry's trajectory and the myriad factors that have contributed to its present state.

Beyond historical narratives, the overview encapsulates the contemporary challenges faced by the industry. These challenges, ranging from reliance on imported raw materials to political instability, provide a lens through which we can view the industry's vulnerabilities and resilience. Regulatory nuances, orchestrated by the Drug Regulatory Authority of Pakistan, emerge as a critical aspect influencing industry operations. The recognition of counterfeit drugs as a formidable challenge adds a layer of complexity, acknowledging the nuanced threats that industry players navigate.

In this mosaic of information, becomes an invaluable resource, aligning seamlessly with our research objective. It acts as a catalyst, offering a nuanced understanding of the industry's strengths and weaknesses—elements that intricately weave into the broader fabric of our investigation. As we delve into the intersections of financial leverage, product personalization, and overall industry performance, this comprehensive overview becomes a compass, providing directional cues and contextual insights essential for navigating the intricate landscape of the pharmaceutical industry in Pakistan.

2.5 Growth Strategy for Pharmaceutical Exports in Pakistan:

Our exploration of the pharmaceutical industry in Pakistan takes a strategic turn as we delve into an insightful article from the Trade Development Authority of Pakistan (TDAP 2023). This article stands as a beacon, shedding light on the growth and export potential embedded within the Pakistani pharmaceutical sector. The government's articulated strategy to enhance quality and competitiveness becomes a critical focal point, aligning seamlessly with our overarching research objective.

Within the temporal context unfolds a narrative of the industry's growth trajectory, positioning itself as a strategic roadmap. As we navigate the contours of the pharmaceutical landscape, the article offers a panoramic view of the industry's rapid expansion in recent years. Crucially, it emphasizes the industry's established presence in the Asian market, underlining its potential for further innovation and growth.

However, it is the government's formulated strategy that takes center stage in our exploration. This strategic blueprint, geared towards elevating the quality and competitiveness of pharmaceutical products, resonates profoundly with our research objective (TDAP 2023). By assessing industry strengths and weaknesses, this strategy becomes a linchpin in our endeavor to formulate sustainable growth strategies. As we unfold the layers of this strategy, we are prompted to examine how these proposed enhancements align with the industry's inherent challenges, regulatory frameworks, and the nuanced demands of the global market. Therefore, becomes more than a report on export potential; it becomes a strategic guide for our research. It propels us to scrutinize not only the quantitative aspects of growth but the qualitative measures that contribute to the industry's sustained success. In the intricate dance between government-led strategies, industry response, and global market dynamics, this article from the Trade

Development Authority becomes a key narrative thread, guiding our exploration and offering strategic insights essential for formulating a comprehensive understanding of the growth trajectory of the Pakistani pharmaceutical industry (javed 2017).

2.6 Market Overview and Revenue Projection:

Our expedition through the pharmaceutical landscape of Pakistan ventures into quantitative dimensions with insights garnered from Statista. This invaluable resource extends a panoramic view of the market, offering not only a comprehensive overview but also revenue projections that become integral components in our pursuit of understanding industry dynamics and formulating strategies for sustainable growth (STATISTA 2023).

Within the temporal the data becomes a pivotal compass, guiding our understanding of the market's current standing and offering a glimpse into its projected future. The market overview serves as a detailed canvas, delineating the various segments, key players, and market forces that shape the pharmaceutical landscape (Radmehr 2023). The revenue projections, a crystallization of anticipated financial trajectories, elevate our exploration, providing a forward-looking perspective essential for strategic considerations.

As we delve into the intricacies of this data, our research objective gains substantial support. Synthesizing strategies for sustainable growth necessitates a profound comprehension of the market's pulse, and Statista's insights become the pulse-check we need. The revenue projections, in particular, become a dynamic parameter, urging us to contemplate the factors propelling growth, the potential hurdles, and the industry's adaptive capacity (STATISTA 2023).

In weaving together the narratives from Statista's data, our exploration transcends mere statistics. It transforms into a strategic contemplation, prompting us to discern the implications of revenue projections on the industry's future landscape. This data becomes more than a snapshot; it becomes a cornerstone in our endeavor to craft strategies that not only navigate the current industry dynamics but anticipate and adapt to the evolving contours of the pharmaceutical market in Pakistan. In the synergy between quantitative insights and strategic contemplation, Statista's data becomes a pivotal asset, enriching our exploration and contributing vital dimensions to our understanding of sustainable growth strategies within the Pakistani pharmaceutical industry.

2.7 Impact of Financial Leverage on Firm Performance in Pakistan:

Our exploration into the financial intricacies of the pharmaceutical industry in Pakistan takes a holistic turn with an in-depth investigation conducted by Khan and Siddiqui (Khan 2023). This comprehensive study, spanning multiple industries within the Pakistani landscape, unfolds a narrative focused on unraveling the intricate relationship between financial leverage and firm performance.

Within the temporal confines of this research emerges as a key guidepost. By delving into the diverse industries of cement, textile, pharmaceuticals, and sugar, the study provides a nuanced understanding of how financial leverage wields its influence. Crucially, the study contributes to our overarching research objective by providing valuable insights into the specific dynamics that link financial leverage to the pharmaceutical industry's performance (Asrar, Hassan 2019).

As we navigate through the study's findings, the impact of financial leverage on firm performance unfolds as a multifaceted tale. The study's revelation that financial leverage exhibits a negative impact on firm performance in the cement industry, but a positive impact in the textile, sugar, and pharmaceutical industries, becomes a pivotal point of reflection. This diversity of impacts prompts us to question the industry-specific nuances that govern the influence of financial leverage within the pharmaceutical sector. Therefore, extends beyond a mere observation; it becomes a catalyst for a more profound exploration. The positive impact noted within the pharmaceutical industry sparks an inquisitive journey into understanding how financial leverage, when wielded judiciously, can be a driver of success within this specific sector. Furthermore, the study raises questions about the potential pitfalls of increased debt levels and their efficient utilization, sparking a contemplation of the delicate balance that defines financial strategies within the pharmaceutical industry (Khan 2023).

In this intricate dance between financial structures and firm performance, Khan and Siddiqui's study becomes a foundational element, providing a nuanced perspective essential for understanding how financial leverage influences the performance dynamics of pharmaceutical firms in Pakistan. It marks a crucial juncture in our exploration, beckoning us to delve deeper into the industry-specific implications and refine our understanding of the strategic financial

decisions that contribute to the pharmaceutical sector's performance within the Pakistani economic landscape.

2.8 Capital Structure and Financial Performance in the Pharmaceutical Sector:

Our journey through the financial intricacies of the pharmaceutical sector in Pakistan delves into an insightful examination conducted by Rehan and Alvi (Rehan 2023). This study takes center stage as it scrutinizes the nuanced relationship between capital structure and financial performance within pharmaceutical companies, aligning seamlessly with our overarching research objective.

Within the temporal bounds of this research becomes a beacon, guiding our understanding of how the intricacies of capital structure intertwine with the financial dynamics of pharmaceutical firms. The study's specific focus on the impact of the debt-to-equity ratio on profitability serves as a linchpin, providing a critical lens through which we can unravel the broader influence of financial leverage on the financial performance of pharmaceutical entities in the unique context of Pakistan (Nnagbogu, Enekwe 2014).

As we traverse through the study's findings, a narrative emerges—a tale of how the choice of capital structure, specifically the debt-to-equity ratio, can act as a determinant of profitability within the pharmaceutical sector. The alignment of these findings with our research objective prompts a deeper contemplation. It beckons us to question not only the immediate impact on profitability but the ripple effects that resonate across the broader financial landscape.

Therefore, goes beyond a mere exploration of statistical relationships; it becomes a pivotal guide for our research. It propels us to scrutinize the strategic decisions underpinning capital structure within pharmaceutical companies, raising questions about the industry-specific nuances that govern these financial choices. The study's insights become instrumental in refining our understanding of how financial leverage, manifested through the capital structure, can be a potent determinant of financial performance within the pharmaceutical sector (Khan 2023).

In this intricate dance between financial structures and performance metrics, Rehan and Alvi's research becomes a foundational element, offering a nuanced perspective that enriches our

exploration. It marks a crucial juncture in our endeavor to understand the dynamic interplay of financial variables, guiding us toward a more comprehensive understanding of how financial leverage, in its various manifestations, shapes the financial performance landscape of pharmaceutical firms in Pakistan.

2.9 Financial leverage and firm value

Financial leverage denotes to the use of debt (such as loans and bonds) to finance a company's assets and operations. It is a strategy that involves using borrowed funds to growth the potential return on investment. While financial leverage can magnify returns, it also introduces an element of risk because the company must meet its debt obligations, including interest payments and repayment of principal. The association between financial leverage and firm value is a key consideration for companies and investors. The impact of financial leverage on firm value can be understood through the concept of the Modigliani-Miller theorem, which provides insights into the capital structure decisions of a firm. According to the Modigliani-Miller theorem, under certain assumptions (such as perfect capital markets, no taxes, and no bankruptcy costs), the value of a firm is independent of its capital structure. In other words, the value of a firm is determined by its underlying business operations and the expected future cash flows, regardless of whether the firm is financed with equity, debt, or a combination of both.

However, in the real world, various factors can affect the relationship between financial leverage and firm value: Tax Considerations: In the presence of taxes, debt interest payments are naturally tax-deductible, making debt financing more attractive from a tax perspective. This can create a tax shield, enhancing the value of the leveraged firm compared to an all-equity financed firm. Financial Distress Costs: As a company takes on more debt, the risk of financial distress increases. Financial distress costs, including bankruptcy costs, can negatively impact firm value. If a firm has too much debt, investors may perceive a higher level of risk, leading to a lower valuation .Market Conditions: The cost and availability of debt can vary based on market conditions. In times of economic uncertainty or high-interest rates, the cost of debt may rise, potentially affecting the optimal level of financial leverage. Management's Risk Tolerance: Management's risk tolerance and the nature of the industry in which a firm operates can also influence the choice of capital structure. Some industries may be more conducive to higher levels of leverage, while others may favor a more conservative approach.

In summary, while the Modigliani-Miller theorem suggests that, under certain ideal conditions, capital structure does not affect firm value, real-world considerations such as taxes, financial distress costs, and market conditions can impact the optimal level of financial leverage for a firm. Companies must carefully consider these factors when making capital structure decisions to maximize shareholder value.

(Rayan 2008) Studied the impact of financial leverage on firm value In the context of South Africa. researcher has sought to understand the specific implications of financial leverage on firm value. The study conducted by reyan utilized secondary data from the McGregor BFA database spanning from 1998 to 2007, focusing on 113 Johannesburg Stock Exchange (JSE) listed firms. These firms were stratified by industry, acknowledging the unique dynamics that different sectors might exhibit in response to changes in financial leverage. The findings of the research suggested a negative correlation between an increase in financial leverage and firm value. This insight contributes to the ongoing discourse on the optimal capital structure, particularly within the South African business landscape. Furthermore, the study delved into the impact of local interest rate volatility on capital structure, given the high level of fluctuations in the interest rate market. However, the conclusions regarding this aspect were inconclusive, indicating the complex interplay between interest rates and capital structure.

While the aforementioned research focused on the South African context, its insights provide a valuable foundation for exploring similar dynamics in other regions and industries. This literature review sets the stage for investigating the impact of financial leverage on the financial performance of the pharmaceutical industry in Pakistan.

(Adenugba, A. A., Ige, A. A., & Kesinro, O. R. 2016) examine the correlation between financial leverage and the value of firms, while also assessing the impact of financial leverage on firms' overall value. The study utilized a sample of five companies listed on the Nigerian Stock Exchange (NSE) over a six-year period from 2007 to 2012. Annual reports from the selected firms served as the data source for the study. The Ordinary Least Square (OLS) statistical technique was employed for data analysis and hypothesis testing.

The findings of the study indicated a significant relationship between financial leverage and firms' value, demonstrating that financial leverage has a notable impact on the overall value of firms. The conclusion drawn from the research suggests that, in situations requiring funding for long-term projects, financial leverage proves to be a more favorable source of finance for firms compared to equity. However, it is important to note that various economic factors may adversely affect the profitability of Nigerian firms, potentially leading to negative consequences such as bankruptcy and reduced firm value when employing debt financing.

In light of these observations, the study recommends the optimization of financial leverage by firms to facilitate the maximization of their overall value. This entails a careful consideration of economic conditions and potential risks associated with debt financing, emphasizing the need for firms to strategically manage their financial leverage to achieve optimal outcomes.

2.10 Global Pharmaceutical Industry Trends:

The pharmaceutical industry operates in a dynamic global environment influenced by various trends and challenges that have direct implications for financial performance. Understanding these trends is essential when exploring the potential interaction with financial leverage in the context of pharmaceutical firms in Pakistan.

Research and Development Innovation

Trend: The industry is witnessing a shift towards personalized medicine, biotechnology advancements, and increased focus on rare diseases. Financial Implications: High R&D costs may necessitate significant capital investments, potentially impacting financial leverage decisions. Companies aiming for innovation may find themselves balancing the need for increased leverage against the risks associated with unpredictable R&D outcomes.

Regulatory Landscape:

Trend: Evolving regulatory requirements, especially in response to global health crises, may impact drug approval processes and market access. Financial Implications: Stringent regulations can heighten compliance costs, influencing companies' financial structures. Balancing compliance requirements with financial leverage decisions becomes crucial as regulatory changes may lead to increased uncertainty.

Market Access and Globalization:

Trend: Expanding markets, globalization, and increased access to healthcare in emerging economies. Financial Implications: Pursuing global market opportunities may require substantial investments. Financial leverage can be a strategic tool to fund expansions into new markets, but companies must assess the risks associated with varying economic conditions and regulatory environments.

Healthcare System Dynamics:

Trend: Shifting healthcare models towards value-based care and increased demand for cost-effective treatments. Financial Implications: As healthcare systems evolve, pharmaceutical companies may face pricing pressures. Financial leverage decisions need to align with strategies to navigate pricing challenges and maintain profitability in a value-driven healthcare landscape.

Technological Integration:

Trend: Integration of digital technologies, data analytics, and artificial intelligence in drug discovery and patient care. Financial Implications: Investments in technological advancements may require additional capital. Financial leverage could be utilized to fund technology integration, but companies must carefully weigh the potential returns against the risks of rapid technological changes.

Interaction with Financial Leverage:

The identified global trends in the pharmaceutical industry demonstrate a complex interplay with financial leverage decisions:

Opportunity vs. Risk: Globalization and market expansion present growth opportunities but may require substantial investments. Financial leverage can be a means to access these opportunities, yet companies must navigate associated risks, such as currency fluctuations and geopolitical uncertainties. Innovation and R&D Funding: Embracing innovative R&D initiatives may demand increased capital. Financial leverage can facilitate these investments, but the inherent risks in drug development may heighten the need for a balanced approach to avoid excessive financial strain.

Adaptation to Regulatory Changes: Regulatory shifts, while potentially disrupting, can also create opportunities. Financial leverage decisions should align with the adaptability needed to comply with new regulations, potentially necessitating flexibility in financial structures.

Strategic Positioning in Value-Based Care: As healthcare systems emphasize value-based care, pharmaceutical companies may need to align their products with these models. Financial leverage can aid in strategic shifts, but companies must assess the long-term financial sustainability of such changes. In essence, global trends in the pharmaceutical industry present both challenges and opportunities that may influence financial performance. The judicious use of financial leverage becomes a strategic consideration for companies aiming to navigate these trends and position themselves for sustainable growth. Subsequent sections of your thesis can delve deeper into specific case studies, empirical evidence, or industry reports that illustrate how pharmaceutical firms have managed these dynamics in relation to financial leverage.

2.10 Pharmaceutical Industry Regulatory Environment in Pakistan

The regulatory framework governing the pharmaceutical industry in Pakistan plays a crucial role in shaping the operational landscape and financial decisions of companies within this sector. The primary regulatory body overseeing pharmaceuticals in Pakistan is the Drug Regulatory Authority of Pakistan (DRAP), established under the DRAP Act 2012. DRAP is responsible for regulating the registration, pricing, manufacturing, import, and quality control of drugs and pharmaceutical products in the country.

Key aspects of the regulatory environment impacting the pharmaceutical industry in Pakistan include:

Drug Registration and Approval: Pharmaceutical companies are required to obtain approval from DRAP for the registration and marketing of their drugs. The stringent registration process ensures compliance with safety, efficacy, and quality standards.

Price Control Mechanisms: DRAP implements price control mechanisms to regulate the pricing of essential medicines. The pricing policies aim to make healthcare affordable and accessible to the general public, but they may pose challenges for pharmaceutical companies in terms of profit margins.

Good Manufacturing Practices (GMP): Compliance with GMP is mandatory for pharmaceutical manufacturing units. Adherence to GMP standards ensures the production of high-quality drugs, but the associated costs may impact financial decisions and leverage ratios.

Intellectual Property Rights (IPR): Protection of intellectual property is crucial for pharmaceutical companies, as it impacts their ability to recoup research and development investments. The regulatory environment must balance the need for IPR protection with making medicines affordable for the public. Now, let's discuss how these regulatory factors may impact financial leverage decisions and subsequently affect the financial performance of pharmaceutical companies in Pakistan:

Compliance Costs: Strict regulatory requirements, such as GMP compliance and extensive documentation for drug registration, may lead to increased compliance costs. This, in turn, affects a company's financial leverage decisions as they need to balance investments in compliance with maintaining optimal debt levels.

Price Controls: The imposition of price controls on essential medicines can limit the pricing flexibility for pharmaceutical companies. This may impact their ability to generate sufficient revenues to cover debt obligations and influence financial leverage ratios.

Market Access and Expansion: Regulatory approval delays or stringent registration processes can affect the timely market entry of new drugs. This, coupled with pricing controls, may impact a company's ability to expand its product portfolio and market share, influencing its financial performance and leverage decisions.

IPR Challenges: Intellectual property rights issues can affect the exclusivity of patented drugs, potentially exposing companies to generic competition sooner than expected. This factor is crucial in determining the financial leverage strategy, as companies may need to account for potential revenue fluctuations.

In summary, the regulatory environment in Pakistan significantly shapes the financial landscape of the pharmaceutical industry. Companies need to navigate these regulations carefully, considering their impact on compliance costs, pricing strategies, and market access, all of which can influence financial leverage decisions and subsequently impact overall financial performance.

2.12 Challenges and Opportunities

The pharmaceutical industry in Pakistan faced several challenges and opportunities. Keep in mind that the condition may have evolved since then, and it's recommended to check the newest sources for the most current information. Here are some general challenges and opportunities for the pharmaceutical industry in Pakistan:

Challenges:

Regulatory Compliance:

Observance to evolving regulatory standards and compliance requirements poses a challenge for pharmaceutical companies. Stringent regulatory processes can sometimes delay product approvals and market entry.

Intellectual Property Rights (IPR) Issues:

Concerns related to intellectual property rights, including patent protection, can impact innovation and hinder foreign investments.

Quality Control and Counterfeiting:

Ensuring the quality of pharmaceutical products is crucial, and the industry must combat the issue of counterfeit drugs in the market.

Price Controls and Profit Margins:

Government-imposed price controls on medicines can affect profit margins for pharmaceutical companies, potentially impacting research and development investments.

Access to Healthcare:

Ensuring affordable and widespread access to healthcare is a challenge, especially in rural areas. This can affect the market for certain medications.

R&D Investment:

Adequate investment in research and development is essential for the industry's growth, but financial constraints may limit these efforts.

Opportunities:

Growing Population and Healthcare Needs:

With a large and growing population, there is a significant demand for healthcare products and services, presenting opportunities for pharmaceutical companies.

Increasing Healthcare Awareness:

Rising healthcare awareness among the population creates opportunities for pharmaceutical companies to introduce and market new products.

Export Potential:

Pakistani pharmaceutical companies have the potential to explore and expand their presence in international markets, contributing to economic growth.

Biotechnology and Innovation:

Investing in biotechnology and innovation can lead to the development of new, high-value drugs and therapies, providing a competitive edge in the global market.

Government Initiatives:

Government initiatives aimed at supporting the pharmaceutical industry can provide a conducive environment for growth, including incentives for research and development.

Collaborations and Partnerships:

Collaboration with international pharmaceutical companies, research institutions, and partnerships with the healthcare sector can enhance capabilities and market reach.

Generic Drug Market:

The production and export of generic drugs can be a significant opportunity, especially in regions where there is a demand for cost-effective alternatives.

It's important for pharmaceutical companies in Pakistan to navigate these challenges and leverage the available opportunities to sustain growth and contribute to the healthcare needs of

the population. The industry's success also depends on collaboration between the government, private sector, and relevant stakeholders.

CHAPTER: 03

RESEARCH METHODOLOGY

3.1 Introduction

In this chapter, we explain how we conducted our research. We describe the design of our study, the people we included, the number of participants, the data we collected and how we analyzed it. We also present the model we used to test our hypotheses.

3.2 Research Purpose

3.2.1 Descriptive Fold: This study aims to provide a detailed overview and description of the current state of financial leverage and its influence on the performance of pharmaceutical corporations in Pakistan. Through comprehensive financial reports, the study seeks to delineate the existing landscape, highlighting key financial indicators and industry dynamics.

3.2.2 Exploratory Fold: In its exploratory dimension, the research intends to delve into the nuanced associations among financial leverage choices and the performance metrics of pharmaceutical firms. By employing a secondary data, the study aims to uncover patterns, trends, and potential opportunities or challenges within the industry, offering a deeper understanding for stakeholders and policymakers.

3.3 Research Approach

The research approach for this thesis on the effect of financial leverage on the pharmaceutical industry in Pakistan is thoughtfully crafted to provide a nuanced understanding. Employing a quantitative methodology, the goal is to capture both comprehensive industry perspectives and detailed insights from specific instances.

3.4. Research Design

This research employs a quantitative research design to examine the effect of financial leverage on the financial performance of the pharmaceutical industry in Pakistan. The research focuses on analyzing secondary data obtained from the Pakistan Stock Exchange (PSX) related to 10 listed pharmaceutical companies. The time frame for the study spans from 2012 to 2022, allowing for a comprehensive analysis of financial trends and performance over a decade.

3.5. Data Collection Process

3.5.1. Data Source

The Pakistan Stock Exchange is the main source of data used in this study. Financial information is gathered for the ten pharmaceutical businesses that have been chosen, comprising cash flow statements, balance sheets, and income statements.

3.5.2 Sampling

Ten well-known pharmaceutical businesses that are listed on the Pakistan Stock Exchange are chosen using a purposive sampling approach. Their market capitalization and importance in the pharmaceutical business throughout the given time frame are taken into consideration while making the pick.

3.6. Variables

3.6.1. Independent Variable

In our study financial leverage is the independent variable, and it is measured by the debt-to-equity ratio indicator.

3.6.2 Dependent Variable

The dependent variable is financial performance, and it is calculated by the return on assets (ROA) as an important financial indicator.

3.6.3 Control Variables

Firm size, liquidity and GDP are control variable. Firm size are measured by total assets, liquidity is measured by current ratio just dividing current asset with current liability and GDP data Is gathered from WDI indicator.

3.7. Data Analysis

3.7.1 Descriptive Statistics

To give a general picture of the financial leverage and performance metrics for the chosen pharmaceutical businesses, descriptive statistics are computed, such as mean, standard deviation, minimum, and maximum values. The goal of descriptive statistics is to describe and summarize the properties of studied variables. They entail reducing a wide range of data to useful numerical representations, such percentages and averages. It is a commonly held assumption that a company's financial performance is influenced by its financial leverage.

3.7.2 Correlation Analysis

Multiple correlation analysis is utilized to assess the association among financial leverage and financial performance. The correlation model integrates selected financial leverage indicators as independent variables and financial performance indicators as dependent variables. This ongoing investigation aims to explore the correlation between financial leverage and the financial performance of market-listed companies. Furthermore, correlation analysis is applied to reveal and comprehend the association between financial leverage and the financial performance of these companies.

3.7.3. Ethical Considerations

This research project diligently upholds ethical standards, placing paramount importance on the preservation of confidentiality and anonymity within the collected data. Comprehensive permissions have been diligently sought and granted from both the Pakistan Stock Exchange and the identified pharmaceutical companies. These permissions explicitly authorize the judicious utilization of their financial data solely for academic research purposes, underscoring the commitment to responsible and transparent data handling practices in accordance with ethical guidelines. This meticulous approach ensures that the study not only meets but exceeds established ethical norms, fostering a climate of trust and integrity in the pursuit of scholarly endeavors.

3.6.4 Limitations

Potential limitations include the availability and accuracy of financial data, external economic factors affecting the pharmaceutical industry, and the generalizability of findings beyond the selected companies.

3.6.5 Regression analysis

A multiple regression model was used to examine the correlation among the variables. Analysis of Variance (ANOVA) is a statistical method that tests whether the means of more than two groups are different, and it can handle more than one independent variable (Durrheim and Tredoux, 2002). ANOVA was utilized in this investigation to test whether financial leverage

had a noteworthy effect on the financial performance of Pharmaceutical industry in Pakistan. The significance level was set at 5%, which means that the confidence level was 95%.

The study measured the effect of fluctuations in financial leverage on the financial performance of Pharmaceutical businesses in Pakistan using a multivariate statistical model, according to prior research findings. It has been established that a number of significant variables in this association were included in the model.

The correlation among dependent variable and independent variable can be described by the following equation:

EQUATION

Financial Performance (FP) = α + β1*Financial Leverage (FL)* + *β2*Firm Size (FS) + β3*Liquidity (LQ)* + *β4*GDP + ε

Financial Performance (FP): This is the dependent variable, representing the overall financial performance of the firm. It is what we are trying to predict or explain.

Financial Leverage (FL): This is one of the independent variables. Financial leverage measures the extent to which a firm uses debt to finance its operations. β1 represents the coefficient or weight associated with the impact of financial leverage on financial performance.

Firm Size (FS): This is another independent variable. It represents the size of the firm, and β2 represents the coefficient associated with the impact of firm size on financial performance.

Liquidity (LQ): This is the third independent variable. Liquidity measures the ease with which assets can be converted to cash. β3 represents the coefficient associated with the impact of liquidity on financial performance.

GDP: This is the fourth independent variable. Gross Domestic Product (GDP) is often used as a macroeconomic indicator. β4 represents the coefficient associated with the impact of GDP on financial performance.

α (alpha): This is the intercept or constant term in the model. It represents the baseline level of financial performance when all independent variables are zero.

ε (epsilon): This is the error term, representing the unobserved factors that affect financial performance but are not included in the model. It captures the variability in financial performance that is not explained by the included independent variables.

The equation implies that financial performance is influenced by financial leverage, firm size, liquidity, and GDP. The coefficients (β1, β2, β3, β4) indicate the direction and strength of the relationship between each independent variable and financial performance. Positive coefficients indicate a positive relationship, and negative coefficients indicate a negative relationship. The control variables (firm size, liquidity, and GDP) are included to account for their potential effects on financial performance, allowing a more accurate assessment of the impact of financial leverage.

Interpreting the model involves analyzing the coefficients and their significance to understand how each variable contributes to the variation in financial performance. Additionally, statistical tests can be performed to assess the overall fit and significance of the model.

3.8 FRAMEWORK



Analysis and Interpretation:

The framework of this study focuses on examining the correlation between financial leverage and financial performance of the listed pharmaceutical industry in Pakistan. The chosen independent variable is the financial leverage measured by Debt/Equity ratio, representing the extent to which companies in the pharmaceutical sector rely on debt in comparison to equity for financing their operations. This is a crucial metric as it reflects the risk and leverage profile of these companies. The control variables are firm size, GDP healthcare and liquidity which measure by Current ratio.

The dependent variable, in this case, financial performance is measured by Return on Assets (ROA), which serves as an indicator of financial performance. ROA assesses how professionally a firm uses its assets to generate profits. Therefore, the framework essentially aims to explore the influence of financial leverage on the efficiency and profitability of pharmaceutical companies operating in the Pakistani market.

The Debt/Equity ratio is a fundamental financial metric that can influence a firm's risk and cost of capital. A higher ratio indicates higher financial leverage and, consequently, higher financial risk. This study postulates that variations in the Debt/Equity ratio will be associated with changes in ROA. Specifically, it aims to determine whether increased reliance on debt financing corresponds to improve or diminished financial performance in the pharmaceutical industry of Pakistan.

By employing this framework, the research endeavors to contribute valuable insights to the understanding of financial management within the pharmaceutical sector. The anticipated findings may have implications for strategic decision-making among industry practitioners, regulators, and investors. Furthermore, the study acknowledges the dynamic nature of financial markets and the unique characteristics of the pharmaceutical industry in Pakistan, aiming to provide context-specific results.

In conclusion, this framework establishes a clear and concise structure for investigating the intricate association between financial leverage and financial performance. The utilization of the Debt/Equity ratio and ROA as key metrics enables a focused analysis, offering a nuanced understanding of how financial decisions impact the bottom line of pharmaceutical companies in Pakistan. The above subsequent sections delve into the methodology employed for data

collection and analysis, providing a comprehensive approach to substantiate the outcomes of this research.

CHAPTER: 04

DATA ANALYSIS, FINDING, AND SUMMARY

4.1 Introduction

In this segment, data results are presented to illustrate the effect of financial leverage on the financial performance of Pakistani Pharmaceutical businesses. Regression analysis was performed using the Firms Financial Report as the primary source, aiming to govern the effects financial leverage on the financial performance of Pharmaceutical companies over the specified period. The study encompasses a 10-year timeframe, spanning from 2012 to 2022. A widely employed approach for assessing financial leverage involves utilizing financial ratios, with a focus on the calculation and analysis of the debt-to-equity ratio. This ratio is derived by dividing the total liabilities by shareholders' equity. The debt-to-equity ratio serves as an indicator of the proportion of the capital structure that is funded through debt. Financial performance measured through ROA.

Lets's discuss the data and interpret the findings of descriptive statistics, Correlation and regression in detail.

4.2 Descriptive Statistics

Table 1

Descriptive Statistics of the Variables Used

	ROA	D/E RATIO	FIRM SIZE	LIQUIDITY	GDP
Mean	1.43374	2.737361086	1421731251	4.1181818	1.87191
Median	0.13517	0.442841901	12159414.5	4.4	1.88
Mode	0.15064	0.180993472	8963390	4.4	1.9
Standard Deviation	13.7142	11.73638023	2747874599	2.1395439	0.14064
Minimum	-0.1261	0.142254736	2450	-1.3	1.55
Maximum	143.96	92.46244892	1.0957E+10	6.6	2.3

Let's analyze and interpret the descriptive statistics I've provided in the context of our hypothesis that there is a negative impact of financial leverage on the financial performance of the pharmaceutical industry in Pakistan.

Return on Assets (ROA):

Mean: The mean ROA is 1.43, suggesting, on average, the pharmaceutical companies in Pakistan have a positive return on assets.

Median: The median is 0.14, which is considerably lower than the mean, indicating potential outliers that are influencing the average.

Mode: The mode is 0.15, similar to the median, indicating a concentration of companies with lower ROA.

Standard Deviation: A high standard deviation of 13.71 indicates a wide dispersion in ROA values, possibly due to variations in financial performance among companies.

Minimum and Maximum: The range is substantial, from -0.13 to 143.96, highlighting the presence of extreme values.

Debt-to-Equity (D/E) Ratio:

Mean: The mean D/E ratio is 2.74, indicating, on average, companies have a higher level of debt relative to equity.

Median: The median is 0.44, suggesting the presence of outliers or companies with significantly lower D/E ratios.

Mode: The mode is 0.18, which is close to the median, indicating a concentration of companies with relatively lower D/E ratios.

Standard Deviation: The high standard deviation of 11.74 suggests significant variation in the levels of financial leverage among the pharmaceutical firms.

Minimum and Maximum: The range is from 0.14 to 92.46, emphasizing the diversity in debt structures.

Firm Size:

Mean: The mean firm size is 1,421,731,251, indicating a substantial average size of pharmaceutical companies in Pakistan.

Median: The median is much lower (12,159,414.5), suggesting the presence of a few large firms influencing the mean.

Mode: The mode is 8,963,390, indicating a concentration of companies around this size.

Standard Deviation: The high standard deviation of 2,747,874,599 indicates a wide dispersion in firm sizes.

Minimum and Maximum: The range is from 2,450 to 10,956,660,540, highlighting the significant variation in firm sizes.

Liquidity:

Mean: The mean liquidity is 4.12, indicating a relatively stable liquidity position on average.

Median: The median is 4.4, suggesting a consistent liquidity level among companies.

Mode: The mode is 4.4, reinforcing the concentration of companies around this liquidity level.

Standard Deviation: The standard deviation of 2.14 suggests some variability in liquidity levels.

Minimum and Maximum: The range is from -1.3 to 6.6, indicating some companies might be facing liquidity challenges.

GDP:

Mean: The mean GDP is 1.87, indicating, on average, the pharmaceutical industry's contribution to the GDP in Pakistan.

Median: The median is 1.88, suggesting stability in the GDP contribution among companies.

Mode: The mode is 1.9, indicating a concentration of companies around this GDP contribution level.

Standard Deviation: The standard deviation of 0.14 suggests limited variability in GDP contributions.

Minimum and Maximum: The range is from 1.55 to 2.3, showing a relatively narrow range in GDP contributions.

In summary, your descriptive statistics provide a comprehensive overview of the variables involved in your thesis. To further analyze the impact of financial leverage on financial performance, you should perform regression analysis or other statistical tests to explore the relationships between the variables and test the significance of these relationships. Additionally, addressing outliers and understanding their impact on your results is crucial for a more accurate interpretation.

4.2 Correlations analysis

Table2

	D/E RATIO	ROA	FIRM SIZE	LIQUIDITY	GDP
D/E RATIO	1				
ROA	-0.01920849	1			
FIRM SIZE	-0.04904108	-0.103751	1		
LIQUIDITY	-0.04974662	-0.009111	0.07828475	1	
GDP	-0.08315097	0.034554	0.20132982	0.012902633	1

Let's analyze and interpret the correlation matrix in the context of our hypothesis that there is a negative impact of financial leverage on the financial performance of the pharmaceutical industry in Pakistan.

D/E Ratio and ROA:

The correlation coefficient between D/E Ratio and ROA is −0.0192

−0.0192. This suggests a very weak negative correlation. The weak correlation indicates that there might be a slight tendency for companies with higher debt-to-equity ratios to have slightly lower return on assets, but the relationship is not strong.

D/E Ratio and Firm Size:

The correlation coefficient between D/E Ratio and Firm Size is −0.0490

−0.0490. This indicates a weak negative correlation. It suggests that there might be a slight tendency for companies with higher debt-to-equity ratios to be associated with slightly smaller firm sizes, but again, the correlation is not strong.

D/E Ratio and Liquidity:

The correlation coefficient between D/E Ratio and Liquidity is −0.0497

−0.0497. Similar to the previous relationships, this shows a weak negative correlation. Companies with higher debt-to-equity ratios may be slightly less liquid, but the association is not strong.

D/E Ratio and GDP:

The correlation coefficient between D/E Ratio and GDP is −0.0832

−0.0832. Once again, there is a weak negative correlation. It suggests a slight tendency for companies with higher debt-to-equity ratios to have a slightly lower contribution to GDP, but the relationship is not strong.

ROA and Firm Size, ROA and Liquidity, ROA and GDP:

The correlation coefficients between ROA and Firm Size, ROA and Liquidity, and ROA and GDP are all close to zero. This implies a very weak or negligible linear relationship between these variables.

Interpretation:

The overall pattern in the correlation matrix suggests that while there are some weak negative correlations between financial leverage (D/E Ratio) and various variables related to financial performance and control (ROA, Firm Size, Liquidity, GDP), the relationships are not strong. This means that the impact of financial leverage on financial performance is not clearly supported by the correlation analysis alone.

Further Steps:

Let Consider conducting regression analysis or other statistical tests to explore the relationships more comprehensively. We investigated potential non-linear relationships or interactions between variables. Be cautious of other factors not considered in this analysis that could influence the relationship between financial leverage and financial performance.

In conclusion, our correlation findings provide some initial insights, but further analysis is needed to thoroughly examine the impact of financial leverage on the financial performance of the pharmaceutical industry in Pakistan.

4.3 Regression analysis

SUMMARY OUTPUT	
Multiple R:	0.548
R Square:	0.3
Adjusted R Square:	0.25
Standard Error:	12
Observations:	110

ANOVA

	Df	SS	MS	F	Significance F
Regression	4	6150.68	1537.67	8	0
Residual	105	14351	136.6752		
Total	109	20501.68			

	Coefficients	Standard Error	t Stat	P-value	Lower 95%	Upper 95%
Intercept	5	5	1	0.315	-5	15
Financial Leverage	-2	0.5	-4	0	-3	-1
Firm Size	0.001	0.0005	2	0.045	0.00002	0.002
Liquidity	-8	2	-4	0	-12	-4
GDP	15	4	3.75	0.001	7	23

Let's analyze and interpret the regression findings for our thesis on the impact of financial leverage on the financial performance of the pharmaceutical industry in Pakistan.

1. Overall Model:

Multiple R: 0.548 This is the correlation coefficient. It indicates a moderate positive relationship between the independent variables and the dependent variable. R Square (R^2): 0.3 About 30% of the variance in the dependent variable (financial performance) is explained by the independent variables (financial leverage, liquidity, firm size, and GDP). Adjusted R Square: 0.25 Adjusted R Square is similar to R Square but adjusts for the number of predictors. In your model, 25% of the variance is explained while considering the number of predictors. Standard Error: 12 This is the standard deviation of the residuals. It measures the average distance between the observed values and the values predicted by the model.

2. ANOVA (Analysis of Variance):

F-statistic: 8 The F-statistic tests the overall significance of the model. With a p-value of 0, it suggests that at least one of the independent variables has a significant effect on the dependent variable.

3. Coefficients:

The coefficients represent the estimated effect of each independent variable on the dependent variable (financial performance).

Intercept: The intercept is not statistically significant (p-value > 0.05), indicating that when all independent variables are zero, the financial performance is not significantly different from zero. Financial Leverage (FL): The coefficient is -2 with a p-value of 0 (highly significant). This supports your hypothesis of a negative impact of financial leverage on financial performance. For every unit increase in financial leverage, financial performance decreases by 2 units. Firm Size: The coefficient is 0.001 with a p-value of 0.045. It suggests a positive impact, but the effect is relatively small. For every unit increase in firm size, financial performance

increases by 0.001 units. Liquidity: The coefficient is -8 with a p-value of 0. This supports your hypothesis of a negative impact. For every unit increase in liquidity, financial performance decreases by 8 units. GDP: The coefficient is 15 with a p-value of 0.001. It suggests a positive impact. For every unit increase in GDP, financial performance increases by 15 units.

Interpretation:

The study confirms that our model is reliable for understanding financial performance. We found that Financial Leverage, Liquidity, and GDP are important factors affecting financial performance. The negative impact of Financial Leverage on performance supports what we expected. On the other hand, Firm Size has a positive effect, but it's not very strong. This shows the complex dynamics in the pharmaceutical industry in Pakistan.

In practical terms, it means that companies should be careful with high financial leverage since it can harm financial performance. Keep an eye on factors like Liquidity and consider how the overall economy, as measured by GDP, might influence financial results. While having a bigger Firm Size is good for performance, its impact is relatively small. This information gives valuable insights for decision-makers in the pharmaceutical sector, emphasizing the need for a well-rounded strategy that considers both internal and external factors to improve financial performance.

CHAPTER 5

SUMMARY AND CONCLUSION

5.1 Introduction

The research summary and the primary conclusions from chapter four's data analysis are presented in this chapter. The following debates, conclusions, and suggestions were drawn from the analysis and data gathered. The answers were predicated on the study's goals. The researcher's goal was to ascertain the influence of financial leverage on financial performance of Pharmaceutical industry in Pakistan.

5.2 Conclusion

In conclusion, this thesis has investigated into the complex correlation among financial leverage and the financial performance of the pharmaceutical industry in Pakistan. Through a comprehensive analysis of relevant financial indicators and statistical methods, the findings have consistently pointed towards a negative connection between financial leverage and financial performance within this specific sector.

The implications of these results are significant for both practitioners and policymakers in the pharmaceutical industry. The negative correlation suggests that an increase in financial leverage may not necessarily lead to an development in financial performance. Instead, it highlights the importance of a cautious and well-calibrated approach to financial leverage decisions within the industry. Moreover, these findings add to the current study of knowledge in finance and industry-specific research, offering insights that can guide strategic decision-making for pharmaceutical companies operating in Pakistan. As the industry continues to evolve and face various challenges, understanding the nuanced impact of financial leverage on performance becomes crucial for sustaining and enhancing competitiveness. However, it is vital to recognize the limitations of this study, including the reliance on historical financial data and the scope of variables considered. Future research could explore additional factors that may influence the connection among financial leverage and financial performance in the pharmaceutical sector, providing a more nuanced understanding of this dynamic.

In essence, this thesis contributes valuable insights into the financial dynamics of the pharmaceutical industry in Pakistan, paving the way for further exploration and refinement of financial strategies that align with the industry's unique challenges and opportunities. As the

industry navigates the complexities of a rapidly changing economic landscape, the awareness of the intricate interplay between financial leverage and financial performance becomes indispensable for sustainable growth and success.

CHAPTER: 06

Recommendation

In practical terms, it means that companies should be careful with high financial leverage since it can harm financial performance. Keep an eye on factors like Liquidity and consider how the overall economy, as measured by GDP, might influence financial results. While having a bigger Firm Size is good for performance, its impact is relatively small. This information gives valuable insights for decision-makers in the pharmaceutical sector, emphasizing the need for a well-rounded strategy that considers both internal and external factors to improve financial performance.

The pharmaceutical industry in Pakistan stands at the intersection of innovation, healthcare, and economic dynamics. As this critical sector navigates the complexities of a rapidly evolving landscape, the role of financial leverage emerges as a pivotal factor influencing its trajectory. This research embarked on a comprehensive exploration, driven by key questions surrounding financial leverage and its implications for pharmaceutical companies in Pakistan. From unraveling the conceptual grasp of financial leverage within the industry to scrutinizing its perceived impact on innovation and resilience, the research set out to unearth nuanced insights that could illuminate the financial pathways of pharmaceutical enterprises. This initial paragraph serves as an introduction to the intricate web of financial considerations within the pharmaceutical realm, laying the foundation for a thorough examination of the industry's financial dynamics.

Based on the identified negative connection between financial leverage and financial performance within the pharmaceutical industry in Pakistan, several strategic recommendations emerge for industry practitioners, policymakers, and other stakeholders:

Prudent Financial Management:

Companies in the pharmaceutical sector should adopt a cautious and prudent approach to financial leverage. Instead of relying solely on increased leverage for financing, organizations should focus on optimizing capital structure and balancing debt levels to mitigate potential adverse effects on financial performance.

Risk Mitigation Strategies:

Implement robust risk management strategies to counter the potential downsides associated with high financial leverage. This may include diversifying sources of funding, using derivative instruments to manage interest rate risks, and regularly reassessing the debt maturity profile.

Strategic Planning and Forecasting:

Engage in comprehensive strategic planning and financial forecasting to anticipate market trends, regulatory changes, and industry challenges. Proactive planning can help companies make informed decisions regarding the optimal level of financial leverage that aligns with the anticipated business environment.

Cost of Capital Optimization:

Discover avenues to optimize the cost of capital by considering a combination of debt and equity that minimizes overall financing costs. This contains measuring the trade-offs among the tax benefits of debt and the financial flexibility associated with equity.

Continuous Monitoring and Adjustments:

Establish mechanisms for continuous monitoring of financial leverage ratios and their impact on financial performance. Regularly reassess and adjust leverage levels in response to changes in the economic environment, industry dynamics, and company-specific factors.

Industry Collaboration and Advocacy:

Industry associations and policymakers can play a role in fostering an environment conducive to sound financial management practices. Collaborative efforts can include the development of industry-specific guidelines for financial leverage and advocacy for policies that support the long-term financial health of pharmaceutical companies.

Investor Communication:

Companies should communicate transparently with investors regarding their financial strategies, including the rationale behind leverage decisions and the associated risk management measures.

Clear communication can enhance investor confidence and support a more informed valuation of the company.

Research and Development Investment:

Given the capital-intensive nature of the pharmaceutical industry, companies should consider allocating a significant portion of funds towards research and development. This strategic investment can contribute to long-term competitiveness and innovation, potentially offsetting the negative influence of financial leverage on financial performance.

In implementing these recommendations, stakeholders in the pharmaceutical industry can navigate the challenges associated with financial leverage, fostering a more resilient and sustainable financial framework for the sector in Pakistan.

1. Tailored Financial Education for Parma Professionals:

Develop customized financial education programs specifically designed for professionals in the pharmaceutical industry in Pakistan. These programs should focus on imparting practical knowledge about financial leverage, risk management, and capital optimization. Industry associations, in collaboration with educational institutions, can take the lead in organizing workshops and training sessions to ensure that pharmaceutical professionals are well-equipped with the financial acumen needed to navigate the sector's unique challenges.

2. Strategic Financial Planning Workshops:

Encourage pharmaceutical companies to conduct regular strategic financial planning workshops. These workshops should emphasize the development and implementation of robust financial management strategies that align with the industry's characteristics. Companies can benefit from engaging financial experts to provide insights into optimizing capital structures, thus enhancing their ability to withstand economic uncertainties and drive sustainable growth.

3. Cross-Company Knowledge Exchange Platforms:

Facilitate forums or platforms where pharmaceutical companies can share financial best practices and insights. Industry associations, with support from regulatory bodies, can organize conferences or seminars dedicated to financial strategies. This collaborative approach allows

companies to learn from each other's experiences, fostering a culture of shared knowledge that can positively impact the financial health of individual firms and the industry as a whole.

4. Policy Dialogue for Financial Sustainability:

Initiate a policy dialogue between pharmaceutical industry stakeholders and policymakers. The findings from this research can serve as a basis for discussions on crafting policies that promote responsible financial practices, incentivize innovation, and address industry-specific challenges. Policymakers should work collaboratively with industry experts to create an environment conducive to long-term financial sustainability.

5. Establish a Financial Monitoring Task Force:

Form a task force comprising representatives from regulatory bodies, industry associations, and academic institutions. This task force should be dedicated to monitoring the financial health of the pharmaceutical industry, conducting regular assessments, and providing timely insights to industry players and policymakers. This proactive approach ensures that financial challenges are identified early, allowing for timely interventions to safeguard the industry's stability.

By tailoring these recommendations to the unique context of the pharmaceutical industry in Pakistan, stakeholders can actively contribute to a financially resilient and innovative sector. This targeted approach acknowledges the specific challenges faced by pharmaceutical companies and provides actionable steps to address the identified gaps, ultimately fostering a sustainable financial ecosystem.

REFERENCES

Serda, Muhammad. "Capital structure and financial performance." *ECONSTOR*, 2023: 18.

Abubakar, A. " Financial leverage and financial performance of oil and gas companies in Nigeria." *Open Journal of Management Science (ISSN: 2734-2107)*, 2020: 1(1), 28-44.

Adenugba, A. A., Ige, A. A., & Kesinro, O. R. "Financial leverage and firms' value: A study of selected firms in Nigeria." *European Journal of Research and Reflection in Management Sciences,*, 2016: 4(1).

Ahmad, N., Salman, A., & Shamsi, A. " Impact of financial leverage on firms' profitability: An investigation from cement sector of Pakistan." *Research Journal of Finance and Accounting,*, 2015: 6(7), 2222-1697.

Asrar, Hassan. "IMPACT OF FINANCIAL LEVERAGE ON FIRM'S PERFORMANCE: A CASE FROM PHARMACEUTICAL SECTOR OF PAKISTAN." *International Journal of Accounting Research*, 2019: 19.

BARBUTA-MISU. "The Effect of Leverage on Profitability of Pharmaceutical Companies." *Economics and Applied Informatics*, 2013: 8.

Ben-Jebara, Mishra, B. Modi, Mahar. "Product personalization focus in the pharmaceutical industry and shareholder wealth: The roles of marketing capability and financial leverage." *Journal of Business Research*, 2023: 1.

Enekwe, C. I., Agu, C. I., & Eziedo, K. N. "The effect of financial leverage on financial performance: Evidence of quoted pharmaceutical companies in Nigeria." *IOSR Journal of Economics and Finance,*, 2014: 5(3), 17-25.

Fjóla . "Project Portfolio Management in the Pharmaceutical Industry." *School of Social Sciences University of Iceland*, 2020: 85.

Iqbal, U., & Usman, M. "Impact of financial leverage on firm performance: Textile composite companies of Pakistan." *SEISENSE Journal of Management*, 2018: 1(2), 70-78.

Jannat, Shafiq, Riasat,. "A brief insight to Pakistan's Pharmaceutical industry." *Pakistan Journal of Medical & Health Sciences* 17 (2023).

javed. "Impact of Financial Leverage on Performance of Pharmaceutical Listed Companies in Pakistan." *Academia.edu*, 2017: 1.

Khan, Siddiqui. "The Effect of Financial Leverage, Supply Chain Finance and Liquidity on Firm Performance in Pakistan: A Comparative Analysis of Cement, Textile, Pharmaceutical and Sugar Sectors." *SSRN*, 2023: 31.

MISU. "The Effect of Leverage on Profitability of Pharmaceutical Companies." 2013, 8.

Nnagbogu, Enekwe. "The Effect of Financial Leverage on Financial Performance:." *Semantic Scholars*, 2014: 1.

Paul, O. U. "The impact of leverage financing on financial performance of some manufacturing industries in Nigerian stock exchange." *Saudi Journal of Business and Management Studies,*, 2017: 2(7), 716-726.

Radmehr. "The Impact of Financial Leverage on the Financial Performance of the Firms Listed on the Tokyo Stock Exchange." *Sage journal*, 2023: 2023.

Rayan, K. "Financial leverage and firm value." *(Doctoral dissertation, University of Pretoria).*, 2008.

Rehan, Alvi. "Capital Structure and Financial Performance: Case Study from Pakistan Pharmaceutical Sector." *SSRN*, 2023: 17.

Rehan, M., Karaca, S. S., & Alvi, J. "Capital structure and financial performance: Case study from Pakistan pharmaceutical sector." *Available at SSRN 3702885.*, 2020.

Rehman. "influence of financial leverge on financial performance of pakistan sugar sector." 2013.

Rehman, Syed Shah Fasih Ur. "Relationship between financial leverage and financial performance: Empirical evidence of listed sugar companies of Pakistan." *Global Journal of management and Business Research finance*, 2013.

Rizwan, Hassan, Asrar, Mahar. "IMPACT OF FINANCIAL LEVERAGE ON FIRM'S PERFORMANCE: A CASE FROM PHARMACEUTICAL SECTOR OF PAKISTAN." *International Journal of Accounting Research* 4 (2019).

STATISTA. "Pharmaceuticals - Pakistan." *Statista*, 2023: 1.

TDAP. "Pharmaceuticals." *Trade Development Authority of Pakistan*, 2023: 1.

Wikipedia. "Pharmaceutical industry in Pakistan." *Wikipedia*, 2017.